Difference between revisions of "Part:BBa K4156085"
 
Line 11: Line 11:
 
CDD-iRGD activates the host immune response and triggers apoptosis of tumour cells. iRGD tumor-penetrating peptide-modified lysing adenovirus shows enhanced tumor transmission, intra-tumor dissemination and anti-tumor efficacy.
 
CDD-iRGD activates the host immune response and triggers apoptosis of tumour cells. iRGD tumor-penetrating peptide-modified lysing adenovirus shows enhanced tumor transmission, intra-tumor dissemination and anti-tumor efficacy.
  
−
CDD-iRGD activates host immune response and triggers apoptosis of tumor cells. the protein is expressed with the constitutive promoter plac, thus exerting an anti-tumor effect. Therefore, we plan to use CDD-IRGD as a tumor treatment factor
+
CDD-iRGD activates host immune response and triggers apoptosis of tumor cells. the protein is expressed with the constitutive promoter plac, thus exerting an anti-tumor effect. Therefore, we plan to use CDD-IRGD as a tumor treatment factor<sup>[1]</sup>.
 +
 
 +
===References===
 +
 
 +
<i>
 +
1 Chen R, Braun GB, Luo X, Sugahara KN, Teesalu T, Ruoslahti E. Application of a proapoptotic peptide to intratumorally spreading cancer therapy. Cancer Res. Feb 15 2013;73(4):1352-61. doi:10.1158/0008-5472.Can-12-1979
 +
 
 +
</i>
  
 
<span class='h3bb'>Sequence and Features</span>
 
<span class='h3bb'>Sequence and Features</span>

Latest revision as of 11:49, 11 October 2022


CDD-iRGD

CDD-IRGD is Bit1 cell death domain fusion protein with tumour perforator protein.


Usage and Biology

CDD-iRGD activates the host immune response and triggers apoptosis of tumour cells. iRGD tumor-penetrating peptide-modified lysing adenovirus shows enhanced tumor transmission, intra-tumor dissemination and anti-tumor efficacy.

CDD-iRGD activates host immune response and triggers apoptosis of tumor cells. the protein is expressed with the constitutive promoter plac, thus exerting an anti-tumor effect. Therefore, we plan to use CDD-IRGD as a tumor treatment factor[1].

References

1 Chen R, Braun GB, Luo X, Sugahara KN, Teesalu T, Ruoslahti E. Application of a proapoptotic peptide to intratumorally spreading cancer therapy. Cancer Res. Feb 15 2013;73(4):1352-61. doi:10.1158/0008-5472.Can-12-1979

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]